Metabolic phenotyping of human blood plasma: A powerful tool to discriminate between cancer types?

Annals of Oncology

Volumn 27, Issue 1, 2016, Pages 178-184

  Louis, E ^a   Adriaensens, P ^b,c   Guedens, W ^b   Vanhove, K ^a,d   Vandeurzen, K ^d   Darquennes, K ^d   Vansteenkiste, J ^e   Dooms, C ^e   de Jonge, E ^f   Thomeer, M ^a,f   Mesotten, Liesbet ^a,f  

^a HASSELT UNIVERSITY   (Belgium)

^b Biomolecule Design Group   (Belgium)

^c HASSELT UNIVERSITY   (Belgium)

^d Mariaziekenhuis Noord Limburg ^*  (Belgium)

^e UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^f DEPARTMENT OF CARDIOLOGY   (Belgium)

Author keywords

1H NMR spectroscopy; Breast cancer; Lung cancer; Metabolic phenotype; Plasma

Indexed keywords

PHOSPHATIDYLCHOLINE; SATURATED FATTY ACID; SPHINGOMYELIN; TUMOR MARKER; UNSATURATED FATTY ACID;

ACCURACY; ADULT; AGED; ARTICLE; BLOOD ANALYSIS; BLOOD SAMPLING; BREAST CANCER; CANCER CLASSIFICATION; CANCER GRADING; CANCER STAGING; CELL MEMBRANE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; LIPID PEROXIDATION; LUNG ADENOCARCINOMA; MAJOR CLINICAL STUDY; MALE; METABOLOMICS; NEEDLE BIOPSY; PHENOTYPE; PREDICTION; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; SENSITIVITY AND SPECIFICITY; VALIDATION STUDY; VERY ELDERLY; ADENOCARCINOMA; BLOOD; BREAST NEOPLASMS; DIFFERENTIAL DIAGNOSIS; LUNG NEOPLASMS; MIDDLE AGED; YOUNG ADULT;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; BIOMARKERS, TUMOR; BREAST NEOPLASMS; DIAGNOSIS, DIFFERENTIAL; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; PHENOTYPE; YOUNG ADULT;

EID: 84960130187     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdv499     Document Type: Article

References (22)

1. Bag S, Banerjee DR, Basak A et al. NMR ((1)H and (13)C) based signatures of abnormal choline metabolism in oral squamous cell carcinoma with no prominent Warburg effect. Biochem Biophys Res Commun 2015; 459: 574-578.
2. Kumar D, Gupta A, Mandhani A, Sankhwar SN. Metabolomics-derived prostate cancer biomarkers: fact or fiction. J Proteome Res 2015; 14: 1455-1464.
3. Zhang L, Jin H, Guo X et al. Distinguishing pancreatic cancer from chronic pancreatitis and healthy individuals by (1)H nuclear magnetic resonance-based metabonomic profiles. Clin Biochem 2012; 45: 1064-1069.
4. Lindon JC, Nicholson JK. Spectroscopic and statistical techniques for information recovery in metabonomics and metabolomics. Annu Rev Anal Chem 2008; 1: 45-69.
5. Fiehn O. Metabolomics-the link between genotypes and phenotypes. Plant Mol Biol 2002; 48: 155-171.
6. Bervoets L, Louis E, Reekmans G et al. Influence of preanalytical sampling conditions on the 1H NMR metabolic profile of human blood plasma and introduction of the standard preanalytical code used in biobanking. Metabolomics 2015; 11: 1197-1207.
7. Amoedo ND, Valencia JP, Rodrigues MF et al. How does the metabolism of tumour cells differ from that of normal cells. Biosci Rep 2013; 33: 865-873.
8. Munoz-Pinedo C, El Mjiyad N, Ricci JE. Cancer metabolism: current perspectives and future directions. Cell Death Dis 2012; 3: e248.
9. Sciacovelli M, Gaude E, Hilvo M, Frezza C. The metabolic alterations of cancer cells. Methods Enzymol 2014; 542: 1-23.
10. Iurlaro R, Leon-Annicchiarico CL, Munoz-Pinedo C. Regulation of cancer metabolism by oncogenes and tumor suppressors. Methods Enzymol 2014; 542: 59-80.
11. Chen X, Qian Y, Wu S. The Warburg effect: evolving interpretations of an established concept. Free Radic Biol Med 2015; 79: 253-263.
12. Louis E, Bervoets L, Reekmans G et al. Phenotyping human blood plasma by 1HNMR:a robust protocol based on metabolite spiking and its evaluation in breast cancer. Metabolomics 2015; 11: 225-236.
13. Louis E, Vanhove K, Stinkens K et al. Validation of 1H-NMR-based metabolomics as a new, complementary tool for the detection of lung cancer via human blood plasma. In EACR-Precision Medicine for Cancer, Luxembourg, Luxembourg, 2015.
14. Goldstraw P, Crowley J, Chansky K et al. The IASLC Lung Cancer Staging Project:proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours. J Thorac Oncol 2007; 2: 706-714.
15. Singletary SE, Allred C, Ashley P et al. Revision of the American Joint Committee on Cancer staging system for breast cancer. J Clin Oncol 2002; 20: 3628-3636.
16. Armitage EG, Barbas C. Metabolomics in cancer biomarker discovery: current trends and future perspectives. J Pharm Biomed Anal 2014; 87: 1-11.
17. Spratlin JL, Serkova NJ, Eckhardt SG. Clinical applications of metabolomics in oncology: a review. Clin Cancer Res 2009; 15: 431-440.
18. Carrola J, Rocha CM, Barros AS et al. Metabolic signatures of lung cancer in biofluids: NMR-based metabonomics of urine. J Proteome Res 2011; 10: 221-230.
19. Oakman C, Tenori L, Biganzoli L et al. Uncovering the metabolomic fingerprint of breast cancer. Int J Biochem Cell Biol 2011; 43: 1010-1020.
20. Rocha CM, Carrola J, Barros AS et al. Metabolic signatures of lung cancer in biofluids: NMR-based metabonomics of blood plasma. J Proteome Res 2011; 10: 4314-4324.
21. Vesselle H, Schmidt RA, Pugsley JM et al. Lung cancer proliferation correlates with [F-18]fluorodeoxyglucose uptake by positron emission tomography. Clin Cancer Res 2000; 6: 3837-3844.
22. Rysman E, Brusselmans K, Scheys K et al. De novo lipogenesis protects cancer cells from free radicals and chemotherapeutics by promoting membrane lipid saturation. Cancer Res 2010; 70: 8117-8126.